C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2738944
The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/ or of the SERPINA3 gene.
La présente invention concerne l'utilisation de la lipocaline associée à la gélatinase des polynucléaires neutrophiles (NGAL) et/ou de la SERPINA3 en tant que biomarqueurs de lactivation du récepteur des minéralocorticoïdes (MR) chez un patient. Plus particulièrement, la présente invention concerne une méthode permettant de prédire la faculté de réponse dun patient à un traitement par un antagoniste MR ou un inhibiteur daldostérone synthase, ladite méthode consistant à déterminer dans un échantillon biologique obtenu chez ledit patient le niveau d'expression du gène codant pour la NGAL et/ou du gène codant pour SERPINA3.
Farman Nicolette
Jaisser Frederic
Latouche Celine
Sainte-Marie Yannis
Steenman Marja
Inserm (institut National de La Sante Et de La Recherche Medical
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Biomarkers of mineralocorticoid receptor activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers of mineralocorticoid receptor activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers of mineralocorticoid receptor activation will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1993709